1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Colinz Laboratories Ltd

Colinz Laboratories Ltd

BBSE:COLINZ
67.00
INR
+1.89
(+2.90%)
11.10EPS
7.51P/E
209.79MMarket Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
16.7
17.15
17.97
16.71
17.09
16.78
16.63
13.35
15.21
28.83
27.88
25.9
24.33
23.06
Basic EPS, GAAP
0.15
0.21
0.21
0.31
0.5
0.27
0.29
0.45
0.74
1.82
1.93
1.97
2.04
11.1
Free Cash Flow per Basic Share
1.44
0.21
1.28
0.09
0.73
0.25
1.17
4.34
0.94
1.62
4.1
-6.81
10.08
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
13.84
13.48
13.74
14.27
14.77
14.97
14.96
15.95
16.82
32.31
35.52
37.61
39.87
- -
Tangible Book Value per Share
13.84
13.48
13.74
14.27
14.77
14.97
14.96
15.95
16.82
32.31
35.52
37.61
39.87
- -
Basic Weighted Avg Shares
4
5
5
5
5
5
5
5
5
2
3
3
3
3
Sales/Revenue/Turnover
74
79
81
76
79
77
76
62
70
72
70
65
61
58
Operating Margin (%)
2.84
1.99
2.09
1.89
1.75
1.76
1.42
2.28
5.52
7.04
5.87
5.57
4.1
3.06
Depreciation Expense
3
3
3
3
2
2
2
2
2
1
1
1
2
2
Net Income, GAAP
1
1
1
1
2
1
1
2
3
5
5
5
5
28
Effective Tax Rate (%)
47.43
33.66
37.54
- -
- -
21.84
25.91
15.33
29.36
23.74
25.16
19.83
25.34
18.46
Profit Margin (%)
0.9
1.22
1.17
1.85
2.93
1.59
1.72
3.37
4.87
6.31
6.92
7.61
8.38
48.13
Working Capital
30
42
30
32
34
39
42
47
54
59
66
69
75
- -
LT Debt
19
23
16
14
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
63
62
63
65
68
68
68
73
77
81
89
95
100
- -
Return on Invested Capital (%)
1.32
1.25
1.22
- -
- -
1.4
1.07
1.5
3.28
4.41
3.43
2.95
1.82
- -
Return on Capital (%)
1.32
2.07
1.94
- -
- -
2.69
2.44
3.62
4.77
5.93
5.74
5.4
5.35
- -
Return on Common Equity (%)
1.06
1.55
1.52
2.2
3.48
1.79
1.91
2.94
4.53
5.71
5.7
5.39
5.27
- -

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
4
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
3
3
3
Market Capitalization
135
112
210

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
101
- -
Cash, Cash Equivalents & STI
- -
85
- -
Accounts Receivable, Net
- -
8
- -
Inventories
- -
7
- -
Total Current Liabilities
- -
26
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
4
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
4.84%
6.63%
6%
Free Cash Flow
77.81%
-88.36%
-248.12%
Net Income, GAAP
24.17%
21.99%
3.6%
Sales/Revenue/Turnover
-2.41%
0.19%
-6%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
17
19
15
15
65
2026
16
14
14
17
61
2027
12
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
0.54
0.62
0.21
0.6
1.97
2026
0.47
0.56
0.33
0.68
2.04
2027
9.53
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Narayan Kutty Menon
Full Time Employees
62
Sector
Health technology
Industry
Pharmaceuticals: major
Address
A-101, Pratik Industrial Estate Mumbai MA India 400078
IPO Date
Jan 13, 2004
Website
findoc-cll.in
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Colinz Laboratories Limited operates as a pharmaceutical company primarily engaged in the manufacturing, marketing, and distribution of active pharmaceutical ingredients (APIs), pharmaceutical formulations, injectables, and specialty chemicals. The company’s core product portfolio includes generic pharmaceutical drugs, formulations for human use, and contract manufacturing services catering to the global pharmaceutical industry. It serves multiple therapeutic segments and offers its products and services to healthcare providers, pharmaceutical companies, and distributors across India and international markets. Founded in 1991, Colinz Laboratories Limited is headquartered in Mumbai, India. In recent developments, Colinz Laboratories Limited has focused on strategic business expansions by enhancing its manufacturing capabilities and entering new markets through partnerships and collaborations with other pharmaceutical entities. The company has launched new product lines to diversify its portfolio and strengthen its presence in key therapeutic categories. It has also undertaken operational upgrades to meet stringent regulatory requirements and improve overall production efficiency. These initiatives are part of its continued efforts to solidify its position in the pharmaceutical manufacturing sector and expand its geographic footprint. Colinz Laboratories operates primarily within the pharmaceutical manufacturing industry, specializing in APIs and finished formulations. Its customer base includes hospitals, healthcare professionals, pharmaceutical distributors, and multinational companies. The company has subsidiaries and maintains compliance with regulatory frameworks in the countries it operates. It leverages advanced technology and quality standards to support pharmaceutical innovation and supply chain reliability. Overall, Colinz Laboratories Limited distinguishes itself through comprehensive pharmaceutical product offerings, strategic operational improvements over the last two years, and consistent service to diverse healthcare markets across India and abroad.